



# Market Announcement

23 August 2023

---

## Avecho Biotechnology Limited (ASX: AVE) – Trading Halt

### Description

The securities of Avecho Biotechnology Limited ('AVE') will be placed in trading halt at the request of AVE, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Friday, 25 August 2023 or when the announcement is released to the market.

### Issued by

**Melissa Kostopoulos**

Adviser, Listings Compliance

## ASX Announcement

23 August 2023

ASX Market Announcements  
ASX Limited  
Level 4  
525 Collins Street, Rialto, North Tower  
Melbourne VIC 3000

By email only: [melissa.kostopoulos@asx.com.au](mailto:melissa.kostopoulos@asx.com.au)  
[tradinghaltsmelbourne@asx.com.au](mailto:tradinghaltsmelbourne@asx.com.au)

Dear Melissa,

## REQUEST FOR TRADING HALT

Avecho Biotechnology Limited (ASX: AVE) (**the Company**) requests an immediate halt to the trading of the Company's ordinary shares quoted on the Australian Securities Exchange (ASX) in accordance with ASX Listing Rule 17.1.

The trading halt is requested pending the release of information by the Company to the market regarding a capital raising (**purpose**).

In accordance with ASX Listing Rule 17.1, the Company provides the following information in relation to the request:

1. The trading halt is necessary to assist the Company in managing its continuous disclosure obligations as the Company expects to make a material announcement to the market in relation to the stated purpose above.
2. The Company requests that the trading halt remains in place until the earlier of commencement of normal trading on Friday, 25 August 2023, or when the announcement regarding the stated purpose is released to the market.
3. The Company expects to make the announcement to the market before the commencement of normal trading on Friday, 25 August 2023.
4. The Company is not aware of any reason why the trading halt should not be granted or of any further information necessary to inform the market about the trading halt.

Please contact me if you require any further information concerning this matter.

Yours sincerely,



Melanie Leydin  
Company Secretary



### **About Avecho**

Avecho Biotechnology Limited (ASX: AVE) develops and commercialises innovative Human and Animal Health products using its proprietary drug delivery system called TPM® (Tocopherol Phosphate Mixture). TPM® is derived from Vitamin E using unique, proprietary and patented processes and is proven to enhance the solubility and oral, dermal and transdermal absorption of drugs and nutrients.

Avecho's major projects include delivering TPM® enhanced injectable, oral and topical products for the human health market, including the recently announced application of TPM® to cannabinoids. The Company is also developing TPM® to enhance feed efficiency and health of livestock.

See more here - [avecho.com.au](https://avecho.com.au)